Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H20O5 |
| Molecular Weight | 292.327 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CCCCCC(=O)C2=C(O)C=C(O)C=C2CC(=O)O1
InChI
InChIKey=VDUIGYAPSXCJFC-JTQLQIEISA-N
InChI=1S/C16H20O5/c1-10-5-3-2-4-6-13(18)16-11(8-15(20)21-10)7-12(17)9-14(16)19/h7,9-10,17,19H,2-6,8H2,1H3/t10-/m0/s1
| Molecular Formula | C16H20O5 |
| Molecular Weight | 292.327 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22767531Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12527810
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22767531
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12527810
Curvularin (S-curvularin) is a macrocyclic lactone with cytotoxic activity. Curvularin inhibits cell division as well as expression of human inducible nitric oxide synthase (iNOS), an enzyme critically involved in pro-inflammatory immune processes. Also was discovered that S-curvularin is an effective anti-inflammatory compound that may serve as a lead compound for the development of new drugs for the therapy of chronic inflammatory diseases, such as Rheumatoid Arthritis or inflammatory bowel disease. S-curvularin is an inhibitor of iNOS-dependent NO production, acting on the Janus tyrosine kinase-STAT pathway.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04630 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527810 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibitors of inducible NO synthase expression: total synthesis of (S)-curvularin and its ring homologues. | 2008-06 |
|
| Sporogen, S14-95, and S-curvularin, three inhibitors of human inducible nitric-oxide synthase expression isolated from fungi. | 2003-02 |
|
| Curvularin from penicillium baradicum Baghdadi NRRL 3754, and biological effects. | 1976 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527810
To analyze the effect of S-curvularin on human iNOS promoter activity, there was incubated A549/8 cells stably transfected with pNOSII(16)Luc with different concentrations of S-curvularin: 1–100 μg/ml, 3–340 μM. It was shown, S-curvularin inhibited the CM-induced iNOS promoter activity in A549/8-pNOSII(16)Luc cells in a concentration-dependent manner. To study the effect of S-curvularin on STAT1 activation, Western blots using an antibody that detects the tyrosine (Tyr701) phosphorylation of STAT1 (corresponds to STAT1 activation; were performed. Incubation of A549/8 for 5 min with cytokine mixture (CM) resulted in a marked enhancement of STAT1 tyrosine phosphorylation. Coincubation of CM-treated A549/8 cells with -curvularin (100 μM) significantly reduced this STAT1 tyrosine phosphorylation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:54:16 GMT 2025
by
admin
on
Mon Mar 31 19:54:16 GMT 2025
|
| Record UNII |
WT39K5T3BX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Curvularin
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
166071
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
WT39K5T3BX
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
119418
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
10140-70-2
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
C013455
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | |||
|
m3936
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID001017585
Created by
admin on Mon Mar 31 19:54:16 GMT 2025 , Edited by admin on Mon Mar 31 19:54:16 GMT 2025
|
PRIMARY |